News

The Phase II study is a multi-centre, randomized, double-blind, placebo-controlled study to evaluate the effect of inhaled ADC4022.

Cellular Dynamics International have announced that it has entered an agreement with Roche Palo Alto to test candidate drug compounds for cardiotoxicity.

InterMune, Inc., has signed a second drug discovery contract with Evotec.

The prestigious Pittcon Editors' Gold Award has been awarded to the breakthrough benchtop Bruker AXS SMART X2S Crystal-to-Structure(TM) small molecule X-ray system

The agreement provides for the NCI to sponsor a clinical trial of VQD-002 in combination with erlotinib (Tarceva®), an epidermal growth factor receptor inhibitor.

Both parties will work together to identify how compounds such as AVR118, interact with clinically relevant molecular targets associated with cancer.

BellBrook Labs has announced that the U.S. Patent and Trademark Office issued a patent to BellBrook Labs the Transcreener™ HTS Assay platform.

Invitrogen Corporation and Tecan are entering into a collaboration agreement to validate the compatibility of Invitrogen’s reagents with Tecan’s microplate detection instruments.

Invitrogen Corporation and BMG LABTECH Inc. are entering into a collaboration agreement to validate the compatibility of Invitrogen’s reagents with BMG LABTECH’s microplate detection instruments.

The collaborative research and exclusive license agreement will develop new technologies for vaccine research and production.